
Genfit S.A (GNFT) | Stock Overview & Key Data
Genfit S.A Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: €68.53 on February 16, 2015
Explore how other French stocks compare to their 52-week ranges: View FR Market 52-Week Insights
Key Statistics
Financial Highlights
Profitability
Returns and Earnings
Growth
Peer Performance Comparison
Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
---|---|---|---|---|---|---|---|---|---|
Genfit S.A GNFT | 175.01M Mid-cap | 8.23% | -0.87% | 5.88% | 14.00% | -6.04% | -36.67% | -16.18% | -9.04% |
Abivax SA ABVX | 5.59B Large-cap | 7.48% | 1.20% | 1,020.59% | 1,471.13% | 946.70% | 818.07% | 878.18% | 291.17% |
Medincell S.A MEDCL | 879.51M Mid-cap | 14.66% | 47.70% | 64.20% | 103.68% | 51.65% | 75.00% | 378.42% | 261.41% |
Valneva SE VLA | 839.69M Mid-cap | 6.56% | 36.03% | 103.77% | 74.55% | 110.82% | 94.02% | -22.45% | -28.59% |
Nanobiotix NANO | 819.65M Mid-cap | 31.35% | 146.93% | 345.19% | 527.80% | 503.26% | 319.00% | 345.19% | 187.13% |
Inventiva S.A IVA | 742.58M Mid-cap | 2.23% | 12.47% | 91.29% | 85.66% | 139.34% | 207.93% | -15.13% | -58.13% |
Ownership & Short Interest
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is GNFT's 52-week high and low?
- In the last 52 weeks, Genfit S.A reached a high of €5.86 (on October 17, 2024) and a low of €2.62 (on April 7, 2025).
- What is the market cap and P/E ratio for GNFT?
- Curious about Genfit S.A's size and valuation? Its market capitalization stands at 175.01M. When it comes to valuation, the P/E ratio (trailing twelve months) is 103.53, and the forward P/E (looking ahead) is -5.07.
- Does GNFT pay dividends? If so, what's the yield?
- As for dividends, Genfit S.A isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Genfit S.A's main competitors or similar companies to consider before investing?
When looking at Genfit S.A, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Abivax SA
ABVX5.59B Healthcare Biotechnology 818.07% 878.18% Medincell S.A
MEDCL879.51M Healthcare Biotechnology 75.00% 378.42% Valneva SE
VLA839.69M Healthcare Biotechnology 94.02% -22.45% Nanobiotix
NANO819.65M Healthcare Biotechnology 319.00% 345.19% Inventiva S.A
IVA742.58M Healthcare Biotechnology 207.93% -15.13% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Genfit S.A.? (e.g., ROE, Debt/Equity)
- To get a sense of Genfit S.A's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -51.74%, the Debt to Equity ratio from the most recent quarter is 264.74, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for GNFT?
- Looking at Genfit S.A's growth, its revenue over the trailing twelve months (TTM) was €45M. Compared to the same quarter last year (YoY), quarterly revenue grew by -41.80%, and quarterly earnings saw a YoY growth of N/A.
- How much of GNFT stock is held by insiders and institutions?
- Wondering who owns Genfit S.A stock? Company insiders (like executives and directors) hold about 13.23% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 0.70%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.